Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 685 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Crohn's Disease Clear all
Completed No phase listed Observational Results available

Imaging Biomarkers in Crohn's Associated Spondyloarthritis

NCT02709694
View directory record Official record
Conditions
Crohn's Disease, Spondyloarthritis
Interventions
No intervention
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 11, 2026, 9:49 PM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)

NCT04852666
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 11, 2026, 9:49 PM EDT
Completed Not applicable Interventional Results available

The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction

NCT02488005
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ultrasound
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 11, 2026, 9:49 PM EDT
Terminated Phase 2 Interventional Results available

Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

NCT01150890
View directory record Official record
Conditions
Crohn's Disease
Interventions
Brodalumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Dothan, Alabama • Lowell, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 11, 2026, 9:49 PM EDT
Completed Phase 2 Interventional

Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

NCT00101946
View directory record Official record
Conditions
Crohn's Disease
Interventions
683699
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Garden Grove, California • Roseville, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 11, 2026, 9:49 PM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension Study of Brazikumab in Crohn's Disease

NCT03961815
View directory record Official record
Conditions
Crohn's Disease, IBD
Interventions
Brazikumab Induction Dose, Brazikumab Maintenance Dose
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Lincoln, California • Clearwater, Florida • Kissimmee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 11, 2026, 9:49 PM EDT
Completed Phase 2 Interventional

Extension Study of Semapimod 60 mg IV x 3 Days

NCT00741910
View directory record Official record
Conditions
Crohn's Disease
Interventions
Semapimod
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Chicago, Illinois • Great Neck, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 11, 2026, 9:49 PM EDT
Completed Phase 4 Interventional

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

NCT00280956
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 11, 2026, 9:49 PM EDT
Completed No phase listed Observational

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

NCT02423512
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 11, 2026, 9:49 PM EDT
Terminated Phase 1Phase 2 Interventional

Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease

NCT04519671
View directory record Official record
Conditions
Perianal Crohn Disease, Perianal Fistula, Crohn Disease
Interventions
Mesenchymal Stem Cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 11, 2026, 9:49 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

NCT00055367
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Los Angeles, California • Hartford, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 11, 2026, 9:49 PM EDT
Completed Not applicable Interventional

Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life

NCT02322307
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
HealthPROMISE users, Control Group
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 11, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Results available

Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery

NCT00688636
View directory record Official record
Conditions
Crohn's Disease
Interventions
infliximab, placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 72 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 11, 2026, 9:49 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

NCT03476317
View directory record Official record
Conditions
Crohn Disease
Interventions
Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Fluconazole
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 11, 2026, 9:49 PM EDT
Completed Phase 2 Interventional

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

NCT01466374
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, BMS-936557 (Anti-IP-10 Antibody)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
10
States / cities
Santa Monica, California • Winter Park, Florida • Hammond, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 11, 2026, 9:49 PM EDT
Not listed No phase listed Observational

Individualized Infiximab Dosing-Proof of Concept Study

NCT02027727
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
No Intervention
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
6 Years to 23 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 11, 2026, 9:49 PM EDT
Completed Phase 1 Interventional

Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease

NCT01847170
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fecal Microbial Transplantation
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 11, 2026, 9:49 PM EDT
Recruiting Not applicable Interventional

Evaluation of the SMART IBD App in Pediatric IBD

NCT07195123
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), IBD (Inflammatory Bowel Disease), IBD - Inflammatory Bowel Disease, Ulcerative Colitis (UC), Indeterminate Colitis, Crohn Disease (CD), IBD
Interventions
SMART-IBD
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 11, 2026, 9:49 PM EDT
Recruiting Phase 2 Interventional

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542
View directory record Official record
Conditions
Crohn's Disease
Interventions
Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
64
States / cities
Dothan, Alabama • Mobile, Alabama • Coronado, California + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 11, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

NCT01277666
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
48
States / cities
Little Rock, Arizona • Tucson, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 11, 2026, 9:49 PM EDT
Withdrawn Phase 1 Interventional

Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease

NCT03414788
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
PF 06687234, [124I]IB PF 06687234
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 11, 2026, 9:49 PM EDT
Terminated Phase 1Phase 2 Interventional

Fecal Microbial Transplant in Pediatric Crohn's Disease

NCT02272868
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fecal Microbial transplant, Normal Saline, rifaximin+omeprazole+miralax
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
12 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 11, 2026, 9:49 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD

NCT07224113
View directory record Official record
Conditions
IBD, Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD), Ultra Processed Food, Nutrition Assessment, DGBI
Interventions
Handout-Only Intervention, Handout + Video Intervention
Behavioral
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
10 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 11, 2026, 9:49 PM EDT
Active, not recruiting Phase 3 Interventional

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
123
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 11, 2026, 9:49 PM EDT